LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

4.11 6.75

Buy Sell

Overview

Share price change

24h

Current

Min

3.83

Max

4.11

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+293.08% upside

Dividends
By Dow Jones
Next Earnings	10 mar 2026

Market Stats
By TradingEconomics
Market Cap	-24M 231M
Previous open	-2.64
Previous close	4.11

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 mar 2026, 18:13 UTC

Acquisitions, Mergers, Takeovers

Shell to Sell Jiffy Lube to Monomoy in $1.3 Billion Deal -- Update

9 mar 2026, 17:20 UTC

Major News Events

U.S. Ag Industry Calls for Government Intervention on Fertilizer Prices

9 mar 2026, 17:15 UTC

Acquisitions, Mergers, Takeovers

Shell to Sell Jiffy Lube and Premium Velocity to Monomoy for $1.3 Billion

10 mar 2026, 00:00 UTC

Major News Events

Why Iranian Regime Change Would Transform Global Energy Markets -- WSJ

9 mar 2026, 23:52 UTC

Market Talk

Gold Steady; May Be Supported by Dollar's Weakness -- Market Talk

9 mar 2026, 23:50 UTC

Market Talk

Nikkei May Rise as Fears About Higher Energy Prices Ease -- Market Talk

9 mar 2026, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 mar 2026, 23:46 UTC

Market Talk

Major News Events

Correction to Crude Prices Market Talk on March 9

9 mar 2026, 23:42 UTC

Market Talk

Major News Events

Oil Futures Fall Amid Developments That Could Help Supply -- Market Talk

9 mar 2026, 23:08 UTC

Major News Events

Front-Month WTI Futures Drop 7.9% to $87.29/bbl, ICE Data Show

9 mar 2026, 23:07 UTC

Major News Events

Front-Month WTI Futures Fall After Trump Says Iran War Will Be Over 'Very Soon'

9 mar 2026, 21:29 UTC

Acquisitions, Mergers, Takeovers

Fortescue Now Fully Owns Peru's Canariaco Copper Project

9 mar 2026, 21:28 UTC

Acquisitions, Mergers, Takeovers

Fortescue Completes Acquisition of Remaining Alta Copper Shares

9 mar 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 mar 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 mar 2026, 20:47 UTC

Major News Events

The 24 Hours When Oil Markets Went Wild -- WSJ

9 mar 2026, 20:33 UTC

Major News Events

Stock Market Today: Oil Slips, Stocks Bounce on Trump War-Progress Comments Headline -- WSJ

9 mar 2026, 20:14 UTC

Market Talk

Major News Events

Oil Moves Lower As Trump Says War Could End Soon -- Market Talk

9 mar 2026, 19:33 UTC

Major News Events

High Oil Prices Could Crimp Convenience Store Margins -- Barrons.com

9 mar 2026, 19:17 UTC

Market Talk

Major News Events

Prospect of Added Supply From Oil Reserves Ease Inflation Fears -- Market Talk

9 mar 2026, 19:14 UTC

Market Talk

Oil Settles Off Highs As G7 Discusses Tapping Reserves -- Market Talk

9 mar 2026, 19:00 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

9 mar 2026, 18:23 UTC

Market Talk

Major News Events

BofA Drops Canada Rate-Cut Call on Higher Oil Prices -- Market Talk

9 mar 2026, 17:58 UTC

Acquisitions, Mergers, Takeovers

Shell to Sell Jiffy Lube to Monomoy in $1.3B Deal -- Update

9 mar 2026, 17:57 UTC

Acquisitions, Mergers, Takeovers

Activist Investors Target Food Companies as Growth Slows. Lamb Weston Is the Latest. -- Barrons.com

9 mar 2026, 17:41 UTC

Major News Events

U.S. and Western Allies Turn to Reserves to Counteract Gulf Oil Crisis -- WSJ

9 mar 2026, 17:41 UTC

Market Talk

Major News Events

Reports of Saudi Production Shut-Ins Keep Bid in Crude -- Market Talk

9 mar 2026, 17:08 UTC

Market Talk

Canada Rate Outlook Shifts From Long Pause to Late 2026 Hike -- Market Talk

9 mar 2026, 17:04 UTC

Market Talk

Major News Events

Global Forex and Fixed Income Roundup: Market Talk

9 mar 2026, 17:04 UTC

Market Talk

Major News Events

Treasury Yields, Dollar Off Highs as G7 Tackles Oil Shock -- Market Talk

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

293.08% upside

12 Months Forecast

Average 15.33 USD 293.08%

High 25 USD

Low 10 USD

Based on 3 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.